Enzo's Pennsylvania License Could Expand Market for GeneNews Colon Cancer Test, Pending Approval
August 26, 2010
Enzo's Pennsylvania License Could Expand Market for GeneNews Colon Cancer Test, Pending Approval
Enzo has been awarded a license to provide clinical diagnostic services in Pennsylvania, which could help the eventual uptake of ColonSentry, a PCR-based colon cancer risk-stratification test manufactured by Canadian firm GeneNews and for which Enzo has exclusive distribution rights in New York and New Jersey.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Royalties Drive up GeneNews Q1 Revenues Sharply
May 16, 2013 / GenomeWeb Daily News - Royalties Drive up GeneNews' Q2 Revenues
August 10, 2012 / GenomeWeb Daily News - GeneNews Raises $2.5M in Rights Offering
June 12, 2012 / GenomeWeb Daily News - MDx/CDx Focus: Another CDx Deal for Dako, Amgen; NYDOH Clears Enzo to Market ColonSentry
February 22, 2012 / Pharmacogenomics Reporter - GeneNews Presents Positive Data on ColonSentry
September 1, 2010 / Pharmacogenomics Reporter